GE MEDICAL SYSTEMS

The global Next Generation Cancer Diagnostics market is projected to grow from $16.6B in 2023 to $64.6B by 2030, driven by increasing cancer prevalence, personalized medicine advancements, and regulatory approvals. Key technologies include liquid biopsy and NGS, with applications in screening, diagnostics, and treatment monitoring.

The Global Cell Counting Market is projected to grow at a CAGR of 6.20% from 2024 to 2031, reaching USD 16.5 Billion. Factors driving growth include increasing demand for accurate diagnostics, advanced biotechnological research, and automation technology.

The gene expression market is projected to grow from $10.54 billion in 2023 to $18.07 billion in 2028 at a CAGR of 11.5%, driven by precision medicine and technological advancements like RNA gene expression technology.

Microsoft's AI healthcare suite aims to improve patient care, while major institutions like Yale, Harvard, and the University of Michigan explore AI initiatives. However, the rapid adoption of AI in healthcare raises concerns about oversight and potential pitfalls, such as AI's 'black box' nature and reliance on biased data. To ensure safety and fairness, stronger regulations, transparency in AI decision-making, and real-world performance tracking are needed. The FDA's approval process for AI medical devices is currently less extensive than for drugs, and a public database for AI device performance is crucial for accountability. Additional resources and public engagement are essential to shape a responsible use of AI in healthcare.

The cell culture market is projected to grow from $27.66 billion in 2023 to $48.33 billion by 2028, driven by increasing demand for cell therapy and advancements in cell culture technology. Key players are innovating with solutions like the cQrex portfolio to enhance efficiency and productivity.

GBM stem cells and 293T cells were cultured in specific media; bioinformatics analysis used GlioVis and GEO data portals; lentiviral constructs for P4HB shRNA were created; quantitative RT-PCR and Western blot analysis were performed; limit-dilution, cell proliferation, and apoptosis assays were conducted; a mouse model for GBM was established; RNA-seq and ELISA were used for further analysis; statistical methods included ANOVA, log-rank, and t-test.

AI in Medical Imaging Market to reach USD 14826.8 Billion by 2032, growing at a CAGR of 34.7%. AI enhances diagnostic accuracy, reduces errors, and improves efficiency in medical imaging, significantly impacting public health outcomes.

The Biotechnology Reagents & Kits Market, valued at USD 563.19 billion in 2023, is projected to grow at a CAGR of 11.04% to USD 1441.03 billion by 2032, driven by demand from diagnostic labs, research institutions, and pharmaceutical companies. Key players include Thermo Fisher Scientific, Merck KGaA, Danaher Corporation, Agilent Technologies, and Roche Diagnostics. The market is segmented by product type, technology, and application, with North America leading and Asia-Pacific showing rapid growth. Recent developments include collaborations and product launches enhancing diagnostic capabilities.

GE HealthCare, since spinning off from GE in 2023, has grown revenue and invested $2.2 billion into innovation, focusing on AI, digital solutions, and expanding global reach. At its first Investor Day, leaders outlined plans for mid-single-digit organic revenue growth by 2026-2028, emphasizing innovation, new product development, and emerging markets. The company's D3 digital strategy aims to deliver precision care, leveraging AI to address healthcare challenges and improve patient outcomes.

The FDA has expanded 510(k) clearance for the Xenoview 3T MRI Chest Coil, enabling its use on GE HealthCare's 3T MRI platforms for lung ventilation assessment in adults and pediatric patients aged 12 and older. This follows previous clearances for Philips and Siemens Healthineers systems, broadening access to hyperpolarized MRI technology for high-risk lung disease patients.